Navigation Links
DURECT Appoints Dr. Joseph Stauffer as Chief Medical Officer and Executive Vice President, Corporate Strategy
Date:6/16/2009

iewed Investigational New Drug (IND) Applications and New Drug Applications (NDAs) for opiate, non-opiate, anti-inflammatory, and novel pain compounds.

Dr. Stauffer is a founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (IMMPACT). This on-going collaboration between pharma, FDA, NIH, academia and patient advocacy groups helps to develop core domains and outcomes for chronic pain clinical trials. Dr. Stauffer graduated from the Philadelphia College of Osteopathic Medicine and completed residency training in Anesthesiology at the Johns Hopkins University Hospital, where he is currently an Adjunct Assistant Professor in the Department of Anesthesiology and Critical Care Medicine. Dr. Stauffer is a veteran of the U.S. Navy, honorably discharged as a Lieutenant Commander after serving eight years as a Naval Medical Officer. He will complete his MBA in September 2009 as part of the TRIUM Global Executive MBA Program, a joint degree granted by NYU Stern School of Business, HEC School of Management (Paris) and the London School of Economics and Political Science.

"I should also note that Dr. Peter Langecker, DURECT's former Chief Medical Officer, has resigned from DURECT Corporation to pursue another opportunity," stated James E. Brown. "We want to thank Peter for his service to DURECT and wish him well on his future endeavors."

About DURECT Corporation

DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM), and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies may enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for
'/>"/>

SOURCE DURECT Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. DURECT to Present at Merriman Curhan Fords Annual Investor Summit
2. DURECT to Present at UBS Global Life Sciences Conference
3. DURECT to Present at 2007 BIO Investor Forum
4. DURECT to Present at BIO CEO Investor Conference 2008
5. DURECT to Participate in Susquehanna Financial Healthcare Conference
6. DURECT to Participate in Cowen Annual Healthcare Conference
7. DURECT Provides Update on CHRONOGESIC(R) Research Program
8. DURECT to Participate in Morgan Stanley Global Healthcare Conference
9. DURECT Corporation Invites You to Join Its First Quarter 2008 Earnings Conference Call
10. DURECT Corporation Presenting at the 2008 UBS Global Generic and Specialty Pharmaceuticals Conference
11. DURECT Corporation Invites You to Join Its Second Quarter 2008 Earnings Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2014)... BUFFALO, N.Y. A novel compound that targets an ... host of cocaine addiction behaviors, including relapse behavior, a ... research provides strong evidence that this may be a ... no effective medications exist., The UB research was published ... last week. , In the study, the compound, RO5263397, ...
(Date:4/23/2014)... that can rapidly screen a large cell population ... that population has been seriously lacking," said Virginia ... Royal Society of Chemistry journal Chemical Science ... coworkers have developed a novel technique that detects ... Sci. , 2014, DOI: 10.1039/C4SC00578C, http://pubs.rsc.org/en/content/articlelanding/2014/sc/c4sc00578c#!divAbstract ). ...
(Date:4/23/2014)... as the United States, it may come as a surprise ... adequate food due to lack of money or other financial ... the University of Illinois using data from the National Health ... are dealing with hunger are also facing negative health and ... over age 60 faced the threat of hungerthat translates to ...
(Date:4/23/2014)... Occupational and Leisure Time Physical Activity on Mobility Limitation ... midlife increases the risk of mobility limitation in old ... is found in a study which followed up 5,200 ... conducted at the Gerontology Research Center in Finland and ... labor is often repetitive, wears the body and lasts ...
(Date:4/23/2014)... disease has been a rapidly evolving pursuit with ... crook in the research road, scientists have found ... associated with the disease. The report, which appears ... could have important implications for developing novel treatments. ... explain that for years, research has suggested a ...
Breaking Medicine News(10 mins):Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... advanced colorectal cancer as intravenous treatment with a similar ... as those on standard chemotherapy, but the pill caused ... 5-fluorouracil (5-FU), the chemotherapy regimen most commonly used to ... to use and produces fewer side effects, and that's ...
... An experimental estrogen lotion appears to reduce the number of ... from a pivotal-stage trial of the drug Estrasorb. If approved ... therapy in lotion form.// ,The drug's developer Novavax ... lotion reduced by 80% the total number of hot flashes ...
... researchers are warning that blood transfusions can cause a ... to more than 50 deaths// nationwide since 1990. About ... patients receive transfusions each year. Testing for the antibodies ... routine screening of the nation's blood supply. ,The ...
... Women who gain 38 pounds or more while pregnant ... by 40%.,Excess pregnancy weight gain// doesn't increase breast cancer ... for post-menopausal women. ,The study found that ... raise their post-menopausal risk of developing breast cancer by ...
... Food and Drug Administration has approved a new treatment ... radiofrequency energy to// shrink small areas of the cornea, ... Unlike laser in situ keratomileusis (LASIK), in which the ... conductive keratoplasty does not require cutting or tissue removal. ...
... Drug Administration recommends pregnant women to avoid swordfish, shark, ... oysters, marlin, halibut, pike, walleye, white croaker, and largemouth ... and young children to eat only small amounts of ... Food and Drug Administration softened its warning to pregnant ...
Cached Medicine News:
(Date:1/15/2014)... 15, 2014 Reportlinker.com announces that a ... its catalogue: Global ... Systems -- Focus on End Users ... OBJECTIVES A drug delivery system ...
(Date:1/14/2014)... , Jan. 14, 2014 HeartWare International, Inc ... of less invasive, miniaturized circulatory support technologies that are ... that it expects revenues for the fourth quarter of ... 2013 revenues to approximately $208 million. "Our ...
(Date:1/14/2014)... HARRISBURG, Pa. , Jan. 14, 2014 Dynamic Healthcare ... ("GMH"), announced today that it acquired Progressive Home Medical Equipment, ... January 7, 2014. The terms of the acquisition were not ... medical equipment ("DME") company providing a wide range of sleep, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... April 13, 2011 Cephalon, Inc. (Nasdaq: ... CXS Holdings Pty Ltd (Cephalon), has lodged the offer ... for ChemGenex Pharmaceuticals Limited (ASX: CXS) (ChemGenex) with the ... offering a 58 percent premium to the one-month volume ...
... Pharmaceuticals, Inc., the leader in the development of neurosteroids ... of a $3 million grant by the U.S. Department ... the treatment of Fragile-X Syndrome (FXS). Ganaxolone modulates GABA-A ... Early research suggests that normalizing neurosteroid levels with ganaxolone ...
Cached Medicine Technology:Cephalon Lodges Bidder's Statement for A$167 Million Offer for ChemGenex Pharmaceuticals 2Cephalon Lodges Bidder's Statement for A$167 Million Offer for ChemGenex Pharmaceuticals 3Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome 2
Tube for Right Bronchus - Ruschelit™ PVC. Color coded for easy identification of ports, balloons and 15mm connectors. High volume/low pressure cuffs. With Carina hook. X-ray opaque line. Gradua...
Laser resistant tubes for use with CO2 and KTP Lasers., ,Designed for airway management during laser surgery of the larynx or other areas in close proximity to the trachea....
Laryngectomy Tubes with special J-shape for convenient placement through a tracheostomy stoma....
SPIRAL-FLEX® Reinforced Oral/Nasal Cuffed Endotracheal Tubes...
Medicine Products: